山东步长制药股份有限公司关于公司产品续约成功保留在国家医保目录的公告

Core Viewpoint - Shandong Buchang Pharmaceutical Co., Ltd. successfully renewed the inclusion of its products Xuanfei Baidu Granules and Danhong Injection in the National Medical Insurance Directory for 2025, which is expected to positively impact the company's market position and sales performance [1][3]. Product Information - Xuanfei Baidu Granules are indicated for clearing lung heat and detoxifying, used for damp-heat obstructing the lungs, with symptoms including fever, cough, and shortness of breath [1]. - Danhong Injection is used for promoting blood circulation and alleviating pain, indicated for conditions such as chest pain and stroke, with symptoms including chest tightness and limb numbness [2]. Sales Impact - The National Medical Insurance Directory will be officially implemented on January 1, 2026, and the sales performance of the drugs may be influenced by various market factors, indicating a level of uncertainty [3].